Roughly 6 percent of men and women in the United States will be diagnosed with lung and bronchus cancer during their lifetime. While both the incidence and mortality rates have been steadily decreasing in...
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive disease with a grim prognosis. While early-stage PDAC may be removed by surgery, PDACs that have spread beyond the pancreas are generally deemed inoperable. Unfortunately, 80 to...
The FDA approved the use of an immunotherapeutic in combination with chemotherapy to treat certain patients with triple-negative breast cancer.
Steroid used to prevent swelling in the brains of patients with glioblastoma may have “detrimental effect” on treatment with immune checkpoint inhibitors.
The FDA granted approval to expand the use of a minimally invasive biomarker test to identify certain patients with ovarian, lung, breast, or prostate cancer eligible for treatment with specific molecularly targeted therapeutics.
An attempt to learn why some patients have an exceptional response to cancer treatment, and more news of the week from Cancer Today.
Socioeconomic factors and racism can lead to poorer health outcomes for Black Americans.
Artificial intelligence may help predict response to immunotherapy among patients with metastatic melanoma, study reports.
A survey indicates that the pandemic is reducing cancer patients’ willingness to enroll in cancer clinical trials, and more news of the week from Cancer Today.
Disproportionate share of the burden of premature cancer deaths in the United States falls on racial and ethnic minorities and on younger people. More than 4 million potential years of life were lost to...
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More